gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

12. - 15.09.2012, Erlangen

Banner: 57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie

Angiocentric gliomas are characterized by unmethylated MGMT-promoter and do not harbor BRAF or IDH1/2 mutations.

Meeting Abstract

  • David Capper - Universität Heidelberg, Institut für Neuropathologie, Heidelberg, Germany
  • Jörg Felsberg - Universität Heidelberg, Institut für Neuropathologie, Heidelberg, Germany
  • Johannes Hainfellner - Medizinische Universität Wien, Klinisches Institut für Neurologie & Comprehensive Cancer Center, Wien, Austria
  • Heinz W. Pannek - Epilepsiezentrum Bethel, Bielefeld, Germany
  • Matthias Preusser - Medizinische Universität Wien, Universitätsklinik für Innere Medizin I & Comprehensive Cancer Center, Wien, Austria
  • presenting/speaker Volkmar Hans - Evangelisches Krankenhaus Bielefeld gGmbH, Institut für Neuropathologie, Bielefeld, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP6.13

DOI: 10.3205/12dgnn124, URN: urn:nbn:de:0183-12dgnn1240

Veröffentlicht: 11. September 2012

© 2012 Capper et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Angiocentric glioma is a rare epilepsy-associated cerebrocortical tumor of uncertain relationship to other neuroepithelial tumors. Recently IDH1/2 mutations have emerged as a hallmark of diffuse astrocytomas and oligodendrogliomas and BRAF V600E point mutations are common in gangliogliomas and pleomorphic xanthoastrocytomas. The presence and putative role of these mutations in angiocentric glioma is still unclear.

We here analyzed a series of 12 resected angiocentric gliomas from 11 patients for mutations of IDH1/2 and BRAF by immunohistochemistry (H09 and VE1; 12/12 cases) and direct sequencing (8/12 cases). Additionally MGMT promoter methylation was assessed by methylation specific PCR and pyrosequencing in 8/12 cases.

All cases were negative for H09 (IDH1 R132H) and VE1 (BRAF V600E) immunohistochemistry. Consistent with this, sequencing of IDH1, IDH2 and BRAF revealed wild type status in all investigated cases. None of the investigated cases demonstrated a methylated MGMT promoter.

We conclude that IDH1/2 and BRAF mutations are not a common feature of angiocentric glioma. These genetic alterations may be useful for the differentiation of this rare epilepsy-associated tumor type from IDH1 mutated gliomas as well as from BRAF mutated gangliogliomas and pleomorphic xanthoastrocytomas. Furthermore, lack of MGMT promoter methylation might predict temozolomide as unpromising in cases not treatable by surgery or radiotherapy.